Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.82
PRXL's Cash to Debt is ranked higher than
59% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. PRXL: 0.82 )
PRXL' s 10-Year Cash to Debt Range
Min: 0.35   Max: 336.54
Current: 0.82

0.35
336.54
Equity to Asset 0.32
PRXL's Equity to Asset is ranked higher than
56% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. PRXL: 0.32 )
PRXL' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.64
Current: 0.32

0.3
0.64
F-Score: 8
Z-Score: 3.91
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 8.80
PRXL's Operating margin (%) is ranked higher than
86% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. PRXL: 8.80 )
PRXL' s 10-Year Operating margin (%) Range
Min: -1.77   Max: 8.8
Current: 8.8

-1.77
8.8
Net-margin (%) 5.70
PRXL's Net-margin (%) is ranked higher than
85% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. PRXL: 5.70 )
PRXL' s 10-Year Net-margin (%) Range
Min: -18.09   Max: 6.28
Current: 5.7

-18.09
6.28
ROE (%) 21.50
PRXL's ROE (%) is ranked higher than
94% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. PRXL: 21.50 )
PRXL' s 10-Year ROE (%) Range
Min: -15.55   Max: 23.12
Current: 21.5

-15.55
23.12
ROA (%) 6.98
PRXL's ROA (%) is ranked higher than
91% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. PRXL: 6.98 )
PRXL' s 10-Year ROA (%) Range
Min: -7.19   Max: 9.2
Current: 6.98

-7.19
9.2
ROC (Joel Greenblatt) (%) 54.39
PRXL's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. PRXL: 54.39 )
PRXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7.63   Max: 58.04
Current: 54.39

-7.63
58.04
Revenue Growth (%) 18.40
PRXL's Revenue Growth (%) is ranked higher than
89% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. PRXL: 18.40 )
PRXL' s 10-Year Revenue Growth (%) Range
Min: 1   Max: 23.9
Current: 18.4

1
23.9
EBITDA Growth (%) 27.50
PRXL's EBITDA Growth (%) is ranked higher than
95% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. PRXL: 27.50 )
PRXL' s 10-Year EBITDA Growth (%) Range
Min: -10.9   Max: 56.3
Current: 27.5

-10.9
56.3
EPS Growth (%) 40.60
PRXL's EPS Growth (%) is ranked higher than
96% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. PRXL: 40.60 )
PRXL' s 10-Year EPS Growth (%) Range
Min: -26.8   Max: 40.6
Current: 40.6

-26.8
40.6
» PRXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PRXL Guru Trades in Q3 2013

Jim Simons 418,900 sh (+204.65%)
Paul Tudor Jones 9,200 sh (+1.1%)
Vanguard Health Care Fund 2,936,400 sh (unchged)
Ken Fisher 2,629,274 sh (-0.77%)
Chuck Royce 475,000 sh (-14.37%)
Steven Cohen 11,260 sh (-43.04%)
Joel Greenblatt 46,486 sh (-57.22%)
» More
Q4 2013

PRXL Guru Trades in Q4 2013

Steven Cohen 241,514 sh (+2044.88%)
Paul Tudor Jones 18,351 sh (+99.47%)
Vanguard Health Care Fund 4,805,700 sh (+63.66%)
Jim Simons 636,100 sh (+51.85%)
Ken Fisher 2,587,749 sh (-1.58%)
Chuck Royce 455,000 sh (-4.21%)
Joel Greenblatt 22,428 sh (-51.75%)
» More
Q1 2014

PRXL Guru Trades in Q1 2014

Joel Greenblatt 103,542 sh (+361.66%)
Jim Simons 645,300 sh (+1.45%)
Chuck Royce 455,000 sh (unchged)
Vanguard Health Care Fund 4,805,700 sh (unchged)
Steven Cohen Sold Out
Ken Fisher 2,534,004 sh (-2.08%)
Paul Tudor Jones 5,600 sh (-69.48%)
» More
Q2 2014

PRXL Guru Trades in Q2 2014

Joel Greenblatt 287,113 sh (+177.29%)
Paul Tudor Jones 9,100 sh (+62.5%)
Jim Simons 736,900 sh (+14.19%)
Vanguard Health Care Fund 5,077,400 sh (+5.65%)
Chuck Royce 455,000 sh (unchged)
Ken Fisher 2,475,274 sh (-2.32%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 177.29%0.12%$43.94 - $55.47 $ 63.7427%287113
Joel Greenblatt 2014-03-31 Add 361.66%0.07%$45.18 - $56.94 $ 63.7425%103542
Vanguard Health Care Fund 2013-12-31 Add 63.66%0.26%$38.93 - $54.85 $ 63.7440%4805700
Joel Greenblatt 2013-12-31 Reduce -51.75%0.04%$38.93 - $54.85 $ 63.7440%22428
Joel Greenblatt 2013-09-30 Reduce -57.22%0.12%$46.43 - $51.33 $ 63.7430%46486
Joel Greenblatt 2013-03-31 Reduce -25.52%0.07%$29.59 - $39.54 $ 63.7483%115560
Joel Greenblatt 2012-09-30 Add 64.33%0.11%$26.98 - $31.09 $ 63.74122%139526
Joel Greenblatt 2012-06-30 Add 37.93%0.05%$25 - $28.38 $ 63.74141%84905
Joel Greenblatt 2012-03-31 Add 165.31%0.09%$20.46 - $28.22 $ 63.74181%61558
Joel Greenblatt 2011-12-31 New Buy0.06%$18.26 - $22.63 $ 63.74216%23202
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.50
PRXL's P/E(ttm) is ranked higher than
92% of the 987 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRXL: 28.50 )
PRXL' s 10-Year P/E(ttm) Range
Min: 6.48   Max: 52.08
Current: 28.5

6.48
52.08
P/B 6.27
PRXL's P/B is ranked higher than
61% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. PRXL: 6.27 )
PRXL' s 10-Year P/B Range
Min: 0.98   Max: 6.27
Current: 6.27

0.98
6.27
P/S 1.62
PRXL's P/S is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. PRXL: 1.62 )
PRXL' s 10-Year P/S Range
Min: 0.33   Max: 1.77
Current: 1.62

0.33
1.77
PFCF 17.09
PRXL's PFCF is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRXL: 17.09 )
PRXL' s 10-Year PFCF Range
Min: 9.43   Max: 99999999.99
Current: 17.09

9.43
99999999.99
EV-to-EBIT 17.80
PRXL's EV-to-EBIT is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRXL: 17.80 )
PRXL' s 10-Year EV-to-EBIT Range
Min: -1612.8   Max: 238
Current: 17.8

-1612.8
238
PEG 1.40
PRXL's PEG is ranked higher than
99% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRXL: 1.40 )
PRXL' s 10-Year PEG Range
Min: 0.22   Max: 25.75
Current: 1.4

0.22
25.75
Shiller P/E 51.24
PRXL's Shiller P/E is ranked higher than
92% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRXL: 51.24 )
PRXL' s 10-Year Shiller P/E Range
Min: 19   Max: 428.17
Current: 51.24

19
428.17
Current Ratio 1.45
PRXL's Current Ratio is ranked higher than
57% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. PRXL: 1.45 )
PRXL' s 10-Year Current Ratio Range
Min: 1.34   Max: 2.36
Current: 1.45

1.34
2.36
Quick Ratio 1.45
PRXL's Quick Ratio is ranked higher than
60% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. PRXL: 1.45 )
PRXL' s 10-Year Quick Ratio Range
Min: 1.34   Max: 2.36
Current: 1.45

1.34
2.36

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 23.18
PRXL's Price/Tangible Book is ranked higher than
64% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. PRXL: 23.18 )
PRXL' s 10-Year Price/Tangible Book Range
Min: 1.3   Max: 22.32
Current: 23.18

1.3
22.32
Price/DCF (Projected) 2.07
PRXL's Price/DCF (Projected) is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRXL: 2.07 )
PRXL' s 10-Year Price/DCF (Projected) Range
Min: 1.71   Max: 8.33
Current: 2.07

1.71
8.33
Price/Median PS Value 1.62
PRXL's Price/Median PS Value is ranked higher than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. PRXL: 1.62 )
PRXL' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 3.82
Current: 1.62

0.58
3.82
Price/Peter Lynch Fair Value 1.79
PRXL's Price/Peter Lynch Fair Value is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRXL: 1.79 )
PRXL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.85   Max: 5.84
Current: 1.79

0.85
5.84
Price/Graham Number 5.38
PRXL's Price/Graham Number is ranked higher than
88% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRXL: 5.38 )
PRXL' s 10-Year Price/Graham Number Range
Min: 1.29   Max: 5.17
Current: 5.38

1.29
5.17
Earnings Yield (Greenblatt) 5.60
PRXL's Earnings Yield (Greenblatt) is ranked higher than
81% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PRXL: 5.60 )
PRXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 14.1
Current: 5.6

0.4
14.1
Forward Rate of Return (Yacktman) 17.26
PRXL's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. PRXL: 17.26 )
PRXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.9   Max: 35.6
Current: 17.26

1.9
35.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PAX.Germany
Parexel International Corporation was incorporated in 1983. The Company provides a range of expertise in clinical research, medical communications, consulting, commercialization and informatics and advanced technology services to the worldwide pharmaceutical, biotechnology, and medical device industries. The Company has three reporting segments: Clinical Research Services ('CRS'), PAREXEL Consulting and Medical Communications Services ('PCMS'), and Perceptive Informatics ('Perceptive'). CRS constitutes its core business and includes all phases of clinical research from 'first-in-man' trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. CRS service offerings include clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. PCMS provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice ('GMP') compliance consulting. In addition, PCMS provides a full spectrum of market development, product development, commercialization, and targeted communications services in support of product launch. PCMS consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. Additionally, PCMS provides reimbursement and market access ('RMA') services. Perceptive provides information technology solutions designed to improve clients' product development processes. Perceptive's portfolio of products and services includes ClinPhone RTSM, medical imaging services, CTMS, EDC, web-based portals, systems integration, and patient diary applications. These solutions are sold individually or in combination, as elements of an eClinical suite. It competes with other biopharmaceutical services companies and other clinical research organizations ('CROs') that provide one or more of the services currently being offered by it. Some of the biopharmaceutical services companies, such as Quintiles Transnational Corporation, Covance Inc., Pharmaceutical Product Development Inc., inVentiv Health, INC Research, and Icon plc, offer services that compete directly with its services at many levels.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK